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g.2012.0Abstract On the trisomy Down syndrome Critical Region (DSCR1) is located the APP gene,
which accelerates amyloid peptide protein (APP) expression leading to cerebral accumulation of
APP-derived amyloid-beta peptides (Ab) and age-dependent cognitive sequelae. Also DSCR1 atten-
uates endothelial cell proliferation and angiogenesis required for tissue repair. The aim of the pres-
ent work is to determine markers of neural degeneration and regeneration in the blood of young
and adolescent Down syndrome (DS) patients as well as controls. Markers of regeneration were
measured in terms of circulating mononuclear cells expressing Nestin and CD34, while markers
of degeneration were measured in terms of plasma Ab42 and advanced glycation end products
receptors (RAGES). Results showed a signiﬁcant increase in plasma Ab42 (20 ± 5.1 vs.
11.9 ± 3.4) and RAGES leucocytes mRNA relative expression (1.9 ± 0.2 vs. 1.1 ± 0.6) in adoles-
cent DS patients compared to young DS. Both parameters were also signiﬁcantly increased in DS
compared to controls: Ab42 (15.4 ± 5.9 vs. 12. 3 ± 4.5); RAGES (1.4 ± 0.5 vs. 0.7 ± 0.2). Nestin
(5.2 ± 1.4 vs. 6.3 ± 0.6) and CD34 (52 ± 2.5 vs. 53 ± 4.7) were non-signiﬁcantly lower in adoles-
cent DS patients compared to young DS, but signiﬁcantly lower in DS patients compared to con-
trols: Nestin (6.3 ± 1.5 vs. 9 ± 4.4); CD34 (54 ± 3.4 vs. 60 ± 4.8). The signiﬁcant decrease in the
number of mononuclear cells bearing Nestin and CD34 markers accompanied by a signiﬁcant
increase in Ab42 and RAGES indicate that degeneration in DS is an ongoing process, which is
not counterbalanced by the regenerative mechanism.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.el-Salam).
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DS is one of the most common and the best known of all mal-
formation syndromes, and accounts for nearly 30% of moder-
ate to severe mental retardation. Its estimated prevalence is
one out of 800 live births [1]. The molecular basis for DS isier B.V. All rights reserved.
50 I.E. Abdel-Meguid et al.the triplication of chromosome 21, referred to as trisomy 21
(Ts21). Chromosome 21 is 45 Mb long and contains 303 genes
[2]. Situated on this chromosome is the Down syndrome Crit-
ical Region (DSCR1) [3].
Located on the long arm of chromosome 21 is the APP gene
that encodes the amyloid precursor protein, APP [4]. Endopro-
teolytic cleavage of APP yields the pathogenic amyloid-b pep-
tides (Ab) that progressively accumulate in the brain as diffuse
and neuritic plaques, the critical factor contributing to the asso-
ciation of DS and Alzheimer disease (AD) [5,6]. Chromosome
21 triplication leads to increased dosage of the APP gene. Over-
expression of APP in affected somatic cells accumulates Ab in
the brain, leading to age dependent cognitive sequelae [7,8]
and reveals evidence of early-onset of AD neuropathology [9].
Recent studies have identiﬁed that the bone marrow con-
tains a highly mobile population of mesenchymal cells that ex-
press mRNA for various markers of early tissue-committed
stem cells (TCSCs), including neural TCSCs and endothelial
TCSCs [10,11]. Neural TCSCs are mobilized into the periphe-
ral blood following neural damage and chemo-attracted to the
damaged neural tissue called circulating neural progenitor cells
(NPCs). NPCs express surface markers identiﬁed as the CD34
and Nestin. Neural progenitor cells expressing Nestin and glial
ﬁbrillary acidic protein that are derived from the bone marrow,
can integrate into the brain and generate microglia, neurons,
and astrocytes and assist in neural regeneration [12,13].
Chromosome 21 distal segment is the site of the gene encod-
ing the synthesis of superoxide dismutase enzyme (SOD). The
excess of genetic information in patients with (DS) produces
an increase in the catalytic activity of (SOD) aswell as other gene
products coded for on chromosome 21 [14]. Excessive SOD has
been shown to increase the oxidative stress measured in terms of
receptors advanced glycation end products (RAGES) mRNA
expression and lipid peroxidation (MDA) [15].
It is well established that genetic condition such as Down
syndrome causes premature aging accompanying global senes-
cence in various organ levels and that the rate of aging in DS
patients is nearly a twofold increase as compared to healthy
subjects [16]. Aging is associated with a decline in immune re-
sponses [17], since it leads to an imbalance between degenera-
tion and regeneration, which is the rate determining step in the
development of the disease.
The aim of the present work is to determine neural markers
of degeneration and regeneration in the blood of DS patients
compared to controls, and compare such markers in young
with adolescent DS. Markers of regeneration were measured
in terms of cells expressing Nestin and CD34 in the blood of
DS patients. Markers of degeneration were measured in terms
of plasma Ab42 and RAGES.
2. Patients and methods
Patients were 40 Down syndrome cases. Age ranged from 2–
15 years (mean 9.3 ± 4.1 year). Controls were 30 matched
healthy normal children, whose age ranged from 2–14 years
(mean 7.1 ± 4.2 years). DS patients were further sub-grouped
into two age groups: below ten years (n= 23) from 2–8 years
(mean 4.1 ± 1.3) and above 10 years (n= 17) from 10–
15 years (mean12 + 1.3). DS patients were selected from cases
already diagnosed by chromosomal karyotyping in the genetic
unit, pediatric department, Cairo University. The selection cri-teria of the patients and controls were to be free from any
infection and in good nutritive status. IQ test was carried
out for DS patients and controls. Developmental milestones
as age of sitting walking and the degree of hypotonia were re-
corded for both groups. Blood was drawn after an informed
consent of the parents in accordance with the current revision
of the 1975 Helsinki Declaration.
3. Biochemical Investigations
3.1. Ab42
This was carried out using Amyloid Beta (Ab) ELISA kit (Mil-
lipore catalog number EZHS42 [18].
4. Reverse transcriptase-polymerase chain reaction (RT-PCR)
for RAGE
Total RNA extracted from Histopaque 1077 (Sigma, Saint
Louis MO, USA) separated lymphocytes using a QIAGEN
RNA extraction kit (QIAGEN Inc, USA). The RNA samples
were reverse transcribed using QIAGEN OneStep RT-PCR kit
(QIAGEN Inc, USA), and processed according to the manu-
facturer’s instructions. Aliquots (5 ll each) from the RT reac-
tion were then used for PCR ampliﬁcation with primer pairs
for RAGE 50-TGGAGACCATCAGTGCCTTTAT and anti-
sense primer 50-AGTTCATA-GTTGCCTGTCTGGG; glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), which was
used as an internal control, was ampliﬁed with the following
primers: sense primer 50-TGAAGG-TCGGAGTCAACG-
GATTTGGT and antisense primers 50-CATGTGGGCCA-
TGAGGTCCACCAC. The polymerase chain reaction
(PCR) was carried out in the following proﬁles: ﬁrst cycle,
94 C for 3 min, 58 C for 1 min, and 72 C for 1 min; second
cycle to 30 cycles, 95 C for 45 s, 58 C for 40 s, and 72 C for
45 s. The ﬁnal cycle was 94 C for 1 min and 72 C for 10 min.
The PCR reaction from RAGE receptors and GAPDH ampli-
cons was separated by 1Æ5% agarose gels, stained with ethi-
dium bromide and the gel image was evaluated under
ultraviolet light and photographed for the appearance of spe-
ciﬁc bands: RAGE 535 bp and GAPDH, 292. Photos were
scanned and quantiﬁcation of each band was carried out using
gene tools version 4. Each quantiﬁed data point was related to
its individual GAPDH [16].
4.1. CD34. and Nestin quantiﬁcation
To quantify EPCs in circulation, peripheral mononuclear cells
were ﬁrst isolated from the blood samples (0.5 mM EDTA).
The isolated cells were labeled with the phycoenythrin (PE)-
conjugated monoclonal nestin antibody and Fluorescein iso-
thiocyanate (FITC) conjugated CD34 (Macs). The stained
cells were washed with phosphate buffered saline and /BSA
and then analyzed by ﬂow cytometry at the Faculty of Medi-
cine, Cairo University [19].
5. Results
Results showed a signiﬁcant increase in plasma Ab 42
(20 ± 5.1 vs. 11.9 ± 3.4) and RAGES leucocytes mRNA rela-
Table 1 Mean and SD of RAGES relative expression and amyloid beta peptide among Down syndrome patients below ten and above
ten compared to each other and compared to controls.
Controls DS Patients P DS patients below 10 (n= 23) DS patients above 10 (n= 17) P
RAGES relative expression 0.7 ± 0.2 1.4 ± 0.5 P< 0.0001 1.1 ± 0.6 1.9 ± 0.2 P< 0.0001
Amyloid beta peptide 42 12. 3 ± 4.5 15.4 ± 5.9 P< 0.01 11.9 ± 3.4 20 ± 5.1 P< 0.0001
Table 2 Mean and SD of mononuclear cells expressing Nestin and
compared to each other and compared to controls.
Controls (n= 30) DS patients (n= 40) P DS pat
Nestin 9 ± 4.4 6.3 ± 1.5 P< 0.0001 6.3 ± 1
CD34 60 ± 4.8 54 ± 3.4 P< 0.0001 53 ± 4
Figure 2 Mean and SD of RAGES relative expression and Ab
42 among Down syndrome patients below ten and above ten
compared to each other and compared to control.
Figure 1 RAGE mRNA and GAPDH mRNA relative expres-
sions among DS compared to controls. M denotes marker, lanes
1–3 represent DS patient, while 4–6 represent controls.
Figure 3 Mean and SD of mononuclear cells expressing CD34 and
compared to each other and compared to controls.
Down syndrome and neural damage 51tive expression (1.9 ± 0.2 vs. 1.1 ± 0.6) in adolescent DS pa-
tients compared to young DS. Both parameters were also sig-
niﬁcantly increased in DS compared to controls: (15.4 ± 5.9
vs. 12. 3 ± 4.5) for Ab 42 and (1.4 ± 0.5 vs. 0.7 ± 0.2) for
RAGES (Table 1, Fig 1 and 2). Nestin (5.2 ± 1.4 vs.
6.3 ± 0.6) and CD34 (52 ± 2.5 vs. 53 ± 4.7) were non-signif-
icantly lower in adolescent DS patients compared to young
DS. The latter parameters were signiﬁcantly lower among
DS patients compared to controls: Nestin (9 ± 4.4 vs.
6.3 ± 1.5) and CD34 (60 ± 4.8 vs. 54 ± 3.4) (Table 2, Fig 3).
6. Discussion
The present study showed a signiﬁcant increase in RAGES
mRNA expression in DS patients compared to controls and
was signiﬁcantly higher among adolescent compared to young
DS patients. This increase can be attributed to the increase of
oxidative stress associatedwithDS patients. RAGE is amember
of the immunoglobulin superfamily of cell surface molecules. It
is a central signal-transduction receptor forAGES. Engagement
of RAGE by these ligands activates key signal transduction
pathways, leading to RAGE-mediated–enhanced expression
of pro-inﬂammatory mediators that could be possible causes
for neuro-degeneration associated with DS [20–22]. Studies car-
ried out on the DS fetal brain cortex showed increased levels of
glycation end products in comparison to controls, providing theCD34 among Down syndrome patients below ten and above ten
ients below 10 (n= 23) DS patients above 10 (n= 17) P
.6 6.2 ± 1.4 P> 0.05
.7 52 ± 2.5 P> 0.05
Nestin among Down syndrome patients below ten and above ten
52 I.E. Abdel-Meguid et al.evidence that accelerated brain glycoxidation occurs very early
in the life of Down syndrome subjects [23].
The signiﬁcant increase in Ab42 in DS compared to controls
in the present study is due to the APP gene, located on the long
arm of extra expressed chromosome 21 [5,7,24]. Aß42 progres-
sively accumulates in the brain as neuritic plaques contributing
to the association of dementia in DS and AD [25,26] and age-
dependent cognitive sequelae [27,28]. The signiﬁcant increase
of Ab42 among adolescent DS compared to young DS gives
an indication that Ab42 increases by aging in DS patients. Pre-
vious studies have shown increased plasma levels of Ab42
among adult DS either non-demented or with prevalent
dementia [29,30]. Ab deposits are found in brain capillaries,
small arteries and arterioles producing cerebral amyloid angi-
opathy (CAA) [31,32] and causing disruption in the blood
brain barrier [33], which has long been recognized as crucial
for maintenance of the brain’s micro-environment. [34].
CD34 was signiﬁcantly lower among DS compared to con-
trols while it was non-signiﬁcantly decreased between adoles-
cent and young DS patients. This ﬁnding gives clue to a
previous in vitro data that showed that the vast majority of
CD34 cells in the bone marrow of adult Ts65Dn mice (trans-
genic model of DS), exhibit a drastic reduction in their
in vitro growth capacity. It showed also that in addition to neu-
ral antigens, cultured CD34 cells from trisomic and diploid
mice also expressed mast cell markers [35] CD34 is an EPC/
hematopoietic stem cell (HSC)-enriched population, which is
capable of differentiation into cardiomyocytes in vitro [36]
and into cardiomyocytes and smooth muscle cells in vivo [37].
Results of the present study showed that mean ± SD of
mononuclear cell expressing Nestin surface marker was signif-
icantly lower among DS patients compared to control. These
results are in agreement with a previous study [38], who found
that Ts21 transgenic mice for DS have reduced numbers of
neural progenitors [39]. Very little data are available describing
neurogenesis in subjects with DS. It has been suggested that
stem cells in the DS brain may be incapable of differentiating
correctly during neurogenesis to form functional neuronal con-
nections leading to the higher incidence of Alzheimer Disease
in DS patients [39]. In vitro studies have shown that both
hematopoietic and neural stem cells (NSC) from patients af-
fected by DS show signs of accelerated aging [40]. Concur-
rently, DS brains weigh less, and the cerebral cortices have
simpler convolutions than age-matched euploid brains
[41,42]. A dramatic reduction in the number of neurons in
the developing cerebral cortex of DS patients has been consis-
tently reported [40,43].
In conclusion the signiﬁcant decrease in the number of
mononuclear cells bearing Nestin and CD34 markers, accom-
panied by a signiﬁcant increase in amyloid b-peptide 42 and
RAGES mRNA indicates that neural degeneration in DS is
an ongoing process, which is not counterbalanced by the
regenerative mechanism.
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